[The use of immune checkpoint inhibitors in routine oncology].
- Schardt J Universitätsklinik für Medizinische Onkologie, Inselspital, Freiburgstr. 41G, 3010, Bern, Schweiz. julian.schardt@insel.ch.
- 2020-09-16
Published in:
- Zeitschrift fur Rheumatologie. - 2020
Anti-CTLA4
Anti-PD1
Immune-mediated adverse events
Ipilimumab
Nivolumab
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Brain Neoplasms
Cell Cycle Checkpoints
Colorectal Neoplasms
Humans
Immunologic Factors
Immunotherapy
Neoplasms
English
BACKGROUND
The advent of immune checkpoint inhibitors has dramatically changed the treatment landscape of many different tumor types. In the clinical routine, humanized antibodies against the immune checkpoints cytotoxic T‑lymphocyte associated protein 4 (CTLA-4) and programmed cell death 1/programmed cell death ligand 1 (PD1/PD-L1) are generally applied.
OBJECTIVE
This article provides an overview of the treatment landscape with immune checkpoint inhibitors, especially for solid tumors in oncology.
MATERIAL AND METHODS
Description and discussion of recent trial results as well as current treatment recommendations and treatment approval indications.
RESULTS
In the clinical routine seven different immune checkpoint inhibitors are applied in oncology: one anti-CTLA‑4 antibody, three anti-PD1 antibodies and three anti-PD-L1 antibodies. On the US market FDA approval for 17 different tumor entities and one agnostic indication (tumors with mismatch repair mechanism deficiency/high microsatellite instability). Long-term remission can be achieved for ca. two thirds of patients with tumor response.
CONCLUSION
Clinical benefits for only a part of patients treated with immune checkpoint inhibitors. The understanding of primary and secondary mechanisms of resistance to immune checkpoint inhibitors has just begun to evolve. Combination strategies of immune checkpoint inhibitors with e.g. chemotherapy, new immune checkpoint inhibitors (e.g. anti-LAG3 antibody) or targeted therapies (e.g. CDK4/6, PARP inhibitors) to improve efficacy are under clinical investigation. Reliable and predictive biomarkers are urgently needed.
The advent of immune checkpoint inhibitors has dramatically changed the treatment landscape of many different tumor types. In the clinical routine, humanized antibodies against the immune checkpoints cytotoxic T‑lymphocyte associated protein 4 (CTLA-4) and programmed cell death 1/programmed cell death ligand 1 (PD1/PD-L1) are generally applied.
OBJECTIVE
This article provides an overview of the treatment landscape with immune checkpoint inhibitors, especially for solid tumors in oncology.
MATERIAL AND METHODS
Description and discussion of recent trial results as well as current treatment recommendations and treatment approval indications.
RESULTS
In the clinical routine seven different immune checkpoint inhibitors are applied in oncology: one anti-CTLA‑4 antibody, three anti-PD1 antibodies and three anti-PD-L1 antibodies. On the US market FDA approval for 17 different tumor entities and one agnostic indication (tumors with mismatch repair mechanism deficiency/high microsatellite instability). Long-term remission can be achieved for ca. two thirds of patients with tumor response.
CONCLUSION
Clinical benefits for only a part of patients treated with immune checkpoint inhibitors. The understanding of primary and secondary mechanisms of resistance to immune checkpoint inhibitors has just begun to evolve. Combination strategies of immune checkpoint inhibitors with e.g. chemotherapy, new immune checkpoint inhibitors (e.g. anti-LAG3 antibody) or targeted therapies (e.g. CDK4/6, PARP inhibitors) to improve efficacy are under clinical investigation. Reliable and predictive biomarkers are urgently needed.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1007/s00393-020-00876-2
- PMID 32936368
- Persistent URL
- https://sonar.ch/global/documents/132514
Statistics
Document views: 35
File downloads:
- Full-text: 0